H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On December 19, H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics to $90 from $60 with a Buy rating on the shares. The firm suggested that the company’s titration strategy has been validated by key opinion leaders. As payer economics push oral GLP-1s toward Tier 1 therapy status, H.C. Wainwright views Structure Therapeutics’ current valuation as a significant arbitrage opportunity when compared to recent industry deal metrics. Due to strong M&A potential and encouraging Phase 2 data, the company is positioned for future growth or acquisition.

Earlier on December 12, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Structure Therapeutics to $125 from $120 while keeping an Overweight rating on the shares. Flynn informed investors that the regulatory and political uncertainties that weighed on the biopharma sector in 2025 are expected to fade in 2026. This shift is projected to redirect market attention toward the industry’s core business performance and pipeline developments rather than government-related risks.

H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1

A day prior to that, Jefferies also raised the firm’s price target on the company to $125 from $79 with a Buy rating on the shares. The firm characterized the recent Phase 2b data for aleniglipron as a solid win, positioning Structure Therapeutics Inc. (NASDAQ:GPCR) as a leader in the space. Jefferies noted that the company likely possesses a best-in-class small-molecule oral GLP1, supported by the most advanced development stage and clinical data that has been significantly de-risked.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical stage global biopharmaceutical company that develops and delivers novel oral small-molecule therapeutics to treat various chronic diseases with unmet medical needs in the US.

While we acknowledge the potential of GPCR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GPCR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.